Guardant Health (NASDAQ:GH – Get Free Report)‘s stock had its “overweight” rating reissued by research analysts at Stephens in a report issued on Friday, Benzinga reports. They presently have a $210.00 target price on the stock. Stephens‘s price target suggests a potential upside of 44.00% from the company’s current price.
A number of other analysts have also weighed in on GH. Mizuho upped their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $210.00 target price on shares of Guardant Health in a report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, October 15th. Stifel Nicolaus boosted their price target on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Rothschild & Co Redburn initiated coverage on shares of Guardant Health in a report on Tuesday, September 8th. They set a “buy” rating and a $203.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $191.48.
Read Our Latest Stock Report on Guardant Health
Guardant Health Price Performance
Guardant Health (NASDAQ:GH – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analysts’ expectations of $350.72 million. Guardant Health’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.74) EPS. On average, research analysts anticipate that Guardant Health will post -3.28 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Steve E. Krognes sold 6,674 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the sale, the director owned 7,906 shares of the company’s stock, valued at approximately $1,389,400.44. This trade represents a 45.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alex M. Azar II sold 826 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the sale, the director directly owned 825 shares in the company, valued at $144,375. This trade represents a 50.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,566 shares of company stock valued at $3,320,185 over the last quarter. Corporate insiders own 5.60% of the company’s stock.
Institutional Trading of Guardant Health
Several institutional investors have recently modified their holdings of GH. Financial Network Wealth Advisors LLC increased its position in Guardant Health by 17.2% during the third quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock worth $75,000 after buying an additional 62 shares during the period. Yousif Capital Management LLC boosted its holdings in shares of Guardant Health by 6.2% in the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock valued at $283,000 after acquiring an additional 93 shares during the period. Allworth Financial LP boosted its holdings in shares of Guardant Health by 12.4% in the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after acquiring an additional 118 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Guardant Health by 14.5% in the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after acquiring an additional 122 shares during the period. Finally, Slow Capital Inc. grew its position in shares of Guardant Health by 0.3% during the third quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock worth $9,397,000 after acquiring an additional 136 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Recent Guardant Health Headlines
These are some of the GH headlines that stood out recently:
- Positive Sentiment: Guardant launched Guardant Reveal Ultra in U.S. clinics, a molecular residual disease platform for solid tumors designed to detect cancer at a sensitivity of one part per million. The launch could expand the company’s testing offering and support future growth. Guardant Health launches Reveal Ultra
- Neutral Sentiment: Insider Terilyn Monroe sold 3,842 shares, reducing her stake by about 15%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less clear-cut signal about the insider’s view of the company. Insider share sale
- Negative Sentiment: A separate commentary argues that GH looks richly priced after its recent run, raising the risk that valuation could limit further gains. Commentary on Guardant Health’s valuation
Guardant Health Company Profile
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Further Reading
- Five stocks we like better than Guardant Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
